Concurrent 5C: Implementation Science to Improve Harm Reduction and HCV/HIV Models of Care for People Who Use Drugs
Tracks
Track 3
| Thursday, October 16, 2025 |
| 4:00 PM - 5:30 PM |
| Hall C |
Details
This session explores how implementation science can optimize care for people who use drugs by addressing barriers to adopting evidence-based interventions and ensuring their long-term sustainability. Experts in the field will present real-world applications of implementation science frameworks to improve integration, uptake, and impact of harm reduction and treatment strategies. The session will highlight innovative approaches to enhance equitable access to HIV and HCV care in diverse settings.
Speaker
Scientia Associate Professor Natalie Taylor
Director of Research
University of New South Wales
Introduction
4:00 PM - 4:05 PMBiography
Associate Professor Oluwaseun Falade-Nwulia
Associate Professor
Johns Hopkins University School of Medicine
Practical use of implementation science in implementation and evaluation of a substance use and HIV care integration model
4:00 PM - 4:20 PMBiography
Dr. Guillaume Fontaine
Assistant Professor
McGill University
Implementation Science to Address Policy Barriers to the Scale Up of Needle and Syringe Programs: From Evidence to Action in 12 Months
4:20 PM - 4:40 PMBiography
Scientia Associate Professor Natalie Taylor
Director of Research
University of New South Wales
Enhancing Hep C Point of Care Testing with Process Mapping: Tools and Strategies for Optimising Care Pathways
4:40 PM - 5:00 PMBiography
Associate Professor Oluwaseun Falade-Nwulia
Associate Professor
Johns Hopkins University School of Medicine
Panel Discussion
5:00 PM - 5:30 PMBiography
Dr. Guillaume Fontaine
Assistant Professor
McGill University
Panel Discussion
5:00 PM - 5:30 PMBiography
Scientia Associate Professor Natalie Taylor
Director of Research
University of New South Wales
Panel Discussion
5:00 PM - 5:30 PMBiography
Chair - Invited
Jacqui Richmond
Workforce Development And Health Service Delivery Lead, Elimination Hepatitis C Australia
Burnet Institute
Chairperson
Natalie Taylor
Director of Research
University of New South Wales
